Age Group	RSV Group A				RSV Group B			
	Anti-G(A) IgG		Anti-G(B) IgG		Anti-G(A) IgG		Anti-G(B) IgG	
	Acute	Convalescent	Acute	Convalescent	Acute	Convalescent	Acute	Convalescent
0-3 mo	1.46 (0.77-2.78)	2.10 (1.34-3.28)	1.14 (0.69-1.90)	1.04 (0.64-1.69)	1.72 (1.10-2.67)	1.38 (0.97-1.97)	1.60 (0.80-3.20)	2.99 (1.66-5.39)
4-6 mo	0.33 (0.19-0.55)	2.38 (1.37-4.15)	0.38 (0.22-0.66)	0.80 (0.56-1.13)	0.28 (0.10-0.76)	0.56 (0.29-1.09)	0.24 (0.11-0.51)	11.8 (5.25-26.6)
7-12 mo	0.10 (0.06-0.16)	6.42 (3.16-13.0)	0.12 (0.08-0.19)	1.20 (0.51-2.79)	0.09 (0.05-0.16)	0.34 (0.16-0.70)	0.07 (0.05-0.09)	19.7 (10.4-37.3)
13-18 mo	0.08 (0.06-0.12)	9.07 (5.63-14.6)	0.10 (0.07-0.16)	1.76 (0.87-3.55)	0.04 (0.02-0.11)	0.20 (0.06-0.73)	0.05 (0.02-0.10)	11.2 (2.99-42.0)
19-36 mo	0.258 (0.12-0.58)	19.0 (9.16-39.6)	0.40 (0.20-0.80)	10.4 (4.75-22.9)	0.20 (0.04-1.08)	1.90 (0.17-21.7)	0.13 (0.05-0.36)	32.4 (18.3-57.3)

Supplemental Table II. Serum IgG concentrations against G of group A and group B in acute phase and convalescent phase

The sera were subjected to ELISA coating RSV G protein of group A or group B. Serum IgG concentrations against G of group A and group B in acute phase and convalescent phase were measured. Data were analyzed in different age groups and in different RSV groups infected during the research period. The sample size in acute phase: 0−3 mo: n = 18 (group A), n = 11 (group B); 4−6 mo: n = 16 (group A), n = 10 (group B); 7−12 mo: n = 16 (group A), n = 10 (group B); 13−18 mo: n = 25 (group A), n = 6 (group B); 19−36 mo: n = 21 (group A), n = 8 (group B). The sample size in convalescent phase: 0−3 mo: n = 18 (group A), n = 11 (group B); 4−6 mo: n = 16 (group A), n = 11 (group B); 7−12 mo: n = 17 (group A), n = 12 (group B); 13−18 mo: n = 25 (group A), n = 6 (group B); 19−36 mo: n = 19 (group A), n = 8 (group B). The data represented the geometric means with corresponding 95%CI.